Brain insulin signaling is a critical pathway that regulates neuronal survival, metabolism, and function. In Parkinson's disease (PD), insulin resistance and impaired insulin-like growth factor (IGF-1) signaling contribute to dopaminergic neuron vulnerability and disease progression[1]. This page covers the molecular mechanisms linking insulin signaling dysfunction to Parkinson's disease pathogenesis.
Brain insulin signaling operates independently of peripheral insulin in many respects, with neurons expressing insulin receptors that respond to locally produced insulin and IGF-1[2]. This signaling is essential for cognitive function, synaptic plasticity, and neuronal survival. The recognition that many neurodegenerative diseases, including PD, Alzheimer's disease, and ALS, feature insulin signaling abnormalities has led to the concept of "type 3 diabetes" — a form of brain-specific insulin resistance[3].
The link between metabolic disorders and neurodegenerative disease has become increasingly clear. Epidemiological studies show that individuals with type 2 diabetes have a 40-60% increased risk of developing Parkinson's disease[4]. This association is not simply due to vascular comorbidities; rather, shared mechanistic pathways involving insulin signaling, mitochondrial dysfunction, and inflammation connect these disorders at a fundamental level.
The insulin signaling cascade involves multiple interconnected pathways[5]:
The insulin receptor (IR) is a tetrameric protein composed of two α-subunits and two β-subunits linked by disulfide bonds[6]. The extracellular α-subunits contain the ligand-binding domain, while the transmembrane β-subunits possess tyrosine kinase activity. Two alternatively spliced isoforms exist:
The brain expresses both isoforms, with IR-A being more abundant in neurons[7]. This isoform distribution has important implications for therapeutic targeting, as IR-A-specific agonists may provide neuroprotective effects without causing peripheral metabolic side effects. The distinct signaling properties of these isoforms have been elucidated through studies showing differential activation of downstream pathways, with IR-A favoring mitogenic signaling through the MAPK pathway while IR-B more efficiently activates metabolic pathways through PI3K/Akt[8].
Receptor Activation: Insulin or IGF-1 binding induces receptor autophosphorylation and activation of receptor tyrosine kinase activity[9]. This triggers a cascade of phosphorylation events that propagate the signal intracellularly. The activated receptor can phosphorylate multiple downstream substrates simultaneously, creating an amplification cascade that ensures robust cellular responses to insulin signaling[10].
IRS Phosphorylation: Activated receptors phosphorylate IRS proteins on tyrosine residues, creating docking sites for PI3K[11]. IRS proteins contain multiple tyrosine phosphorylation sites as well as serine/threonine residues that regulate their function. The balance between tyrosine (activating) and serine (inhibiting) phosphorylation determines IRS activity. In pathological states such as insulin resistance, increased serine phosphorylation creates a feedback inhibition mechanism that protects cells from excessive signaling but also impairs normal physiological responses[12].
PI3K Activation: PI3K converts PIP2 to PIP3, generating second messengers that recruit Akt to the plasma membrane[13]. The p85 regulatory subunit contains SH2 domains that bind phosphorylated IRS, positioning the p110 catalytic subunit at the membrane where it can phosphorylate its lipid substrates. The dynamic regulation of PI3K membrane localization ensures precise spatial and temporal control of signaling[14].
Akt Activation: PDK1 and mTORC2 phosphorylate Akt at multiple sites, fully activating the kinase[15]. Full Akt activation requires phosphorylation at Thr308 (by PDK1) and Ser473 (by mTORC2). Multiple other kinases can phosphorylate additional sites, providing integration points for diverse signals. The complexity of Akt activation allows for fine-tuning of downstream effects based on cellular context and energy status[16].
Downstream Effects: Activated Akt phosphorylates numerous targets including GSK-3β, mTOR, FOXO transcription factors, and BAD[17]. These phosphorylation events regulate cell survival, metabolism, protein synthesis, and gene expression. The breadth of Akt substrates explains its central role in coordinating cellular responses to insulin and growth factors[18].
Multiple studies demonstrate insulin resistance in PD[19]:
Brain Insulin Resistance: Documented through post-mortem studies showing reduced IRS-1 phosphorylation in PD substantia nigra[20]. This reflects impaired insulin receptor signaling at the level of IRS substrate function. The reduction in phospho-IRS-1 is specific to tyrosine residues, indicating a defect in forward signaling rather than general protein loss[21].
Impaired Akt Signaling: Reduced Akt activation in dopaminergic neurons from PD patients[22]. The decrease in Akt phosphorylation correlates with disease severity and provides a mechanistic link to increased neuronal vulnerability. Importantly, the reduction in Akt signaling is observed even in patients without diabetes, suggesting brain-specific insulin resistance[23].
Epidemiological Links: Type 2 diabetes increases PD risk by approximately 40%[24]. Large cohort studies have consistently demonstrated this association, with some showing even higher relative risks in specific populations. A meta-analysis of over 2 million participants confirmed this relationship, with the risk being particularly elevated in younger-onset diabetes[25].
CSF Biomarkers: Reduced insulin-like growth factor levels in PD cerebrospinal fluid[26]. CSF IGF-1 levels correlate with disease progression and may serve as a biomarker for insulin signaling dysfunction. The reduction in CSF IGF-1 is specific to PD compared to other movement disorders, suggesting disease-specific pathway impairment[27].
Impaired Glucose Metabolism: PET studies using fluorodeoxyglucose (FDG) reveal reduced glucose metabolism in specific brain regions in PD[28]. This hypometabolism precedes clinical symptoms in some cases and may reflect underlying insulin resistance. The characteristic pattern of hypometabolism in PD differs from other neurodegenerative diseases, affecting the basal ganglia, thalamus, and frontal cortex[29].
Oxidative Stress: Reactive oxygen species (ROS) damages insulin signaling components including IRS proteins and PI3K[30]. Mitochondrial dysfunction in PD creates a chronic oxidative environment that impairs insulin signaling[31]. The reciprocal relationship creates a vicious cycle where insulin resistance promotes further mitochondrial dysfunction. Antioxidant treatments have been shown to partially restore insulin signaling in experimental models[32].
Inflammation: Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) interfere with IRS function through serine phosphorylation[33]. Neuroinflammation characteristic of PD creates a feedforward loop worsening insulin resistance[34]. The activation of NF-κB and JNK pathways by inflammation directly inhibits insulin signaling. Elevated TNF-α levels in PD brains correlate with markers of insulin resistance[35].
Mitochondrial Dysfunction: ATP deficiency affects insulin signaling which is an energy-intensive process[36]. PINK1 and Parkin mutations affect insulin receptor trafficking, linking genetic forms of PD to insulin signaling dysfunction[37]. The convergence of mitochondrial and insulin signaling pathways in dopaminergic neurons makes them particularly vulnerable. Studies in PINK1-deficient mice show impaired insulin-stimulated Akt activation[38].
Lipid Accumulation: Ceramide accumulation disrupts insulin receptor signaling[39]. Palmitate-induced insulin resistance is well-documented in multiple systems[40]. Elevated ceramide levels in PD brains may represent a mechanistic link between lipid metabolism and neurodegeneration. Ceramide directly inhibits IRS-1 tyrosine phosphorylation and promotes serine phosphorylation[41].
ER Stress: Endoplasmic reticulum stress impairs proper folding and function of insulin signaling proteins[42]. The unfolded protein response (UPR) can directly interfere with IRS phosphorylation and downstream signaling. ER stress markers are elevated in PD brains and correlate with insulin resistance[43].
Insulin resistance in PD follows characteristic patterns that inform our understanding of disease progression[44]:
Early Stage: Insulin resistance may be present in peripheral tissues and nasal epithelium before overt brain involvement[45]. The olfactory bulb and brainstem regions show early changes. This has led to the hypothesis that insulin resistance may begin in peripheral tissues and spread to the brain through as-yet-unidentified mechanisms[46].
Moderate Stage: Insulin signaling impairment extends to the substantia nigra and basal ganglia[47]. Motor symptoms emerge as dopaminergic neurons lose trophic support. The progression of insulin resistance follows the spread of α-synuclein pathology in many cases[48].
Advanced Stage: Widespread insulin resistance affects cortical regions and correlates with cognitive impairment[49]. This pattern mirrors the spread of α-synuclein pathology. In advanced PD, insulin resistance may contribute to the development of dementia in a significant proportion of patients[50].
The PI3K/Akt pathway promotes dopaminergic neuron survival through multiple mechanisms[51]:
Mitochondrial Biogenesis: Akt activates PGC-1α, the master regulator of mitochondrial biogenesis[52]. Enhanced mitochondrial content protects against PD toxins[53]. This pathway is particularly important in dopaminergic neurons given their high energy demands. PGC-1α activation can rescue mitochondrial dysfunction in cellular models of PD[54].
Anti-apoptotic Signaling: Akt phosphorylates and inhibits pro-apoptotic proteins including BAD and caspase-9[55]. This provides critical survival signals for vulnerable dopaminergic neurons[56]. BAD phosphorylation prevents it from inhibiting anti-apoptotic Bcl-2 proteins, allowing cells to resist apoptotic stimuli[57].
Autophagy Regulation: Akt activates mTORC1, which regulates autophagy[58]. Proper autophagic flux is essential for clearance of damaged organelles and protein aggregates[59]. Dysregulated autophagy contributes to α-synuclein accumulation. The relationship between Akt, mTOR, and autophagy is complex, with both activation and inhibition of mTOR having been proposed as therapeutic strategies[60].
Synaptic Plasticity: Akt signaling modulates AMPA receptor trafficking and NMDA receptor function[61]. Synaptic dysfunction in PD may relate to impaired Akt signaling[62]. Akt regulates the localization and function of glutamate receptors, affecting excitatory synaptic transmission[63].
Protein Synthesis: Through mTORC1, Akt regulates translation of proteins required for neuronal survival and function[64]. Local translation in neurites supports synaptic plasticity and axon maintenance. The impairment of protein synthesis pathways in PD contributes to synaptic dysfunction[65].
Multiple mechanisms impair PI3K/Akt signaling in PD[66]:
α-Synuclein Inhibition: α-Synuclein oligomers directly inhibit PI3K activity[67]. This provides a direct link between protein aggregation and survival pathway dysfunction[68]. The toxic effects of α-synuclein extend beyond aggregation to include signaling pathway disruption. Preformed α-synuclein fibrils can propagate between cells and spread pathway impairment[69].
LRRK2 Mutations: Common LRRK2 mutations (G2019S) affect the pathway[70]. LRRK2 and PI3K/Akt intersect at multiple points[71]. G2019S kinase hyperactivity may contribute to pathway dysregulation. LRRK2 can phosphorylate components of the insulin signaling pathway, creating additional points of dysregulation[72].
PINK1/Parkin: Mutations in these genes disrupt Akt signaling through multiple mechanisms[73]. PINK1 can directly phosphorylate Akt, and loss of PINK1 function impairs this activation. Parkin-mediated ubiquitination of signaling proteins is altered in insulin resistance[74].
Mitochondrial Toxins: MPTP, rotenone, and 6-OHDA all cause Akt dephosphorylation[75]. This represents a common final pathway for toxin-induced dopaminergic degeneration[76]. All known PD-inducing toxins converge on the PI3K/Akt pathway, explaining the similar phenotypes they produce[77].
IRS-1 is the major insulin receptor substrate in the brain[78]:
Tyrosine Phosphorylation: Required for downstream PI3K/Akt activation. Reduced in PD brains[79]. The decrease in tyrosine phosphorylation represents a specific defect in insulin signaling rather than reduced protein expression. Total IRS-1 levels may be unchanged or even increased in PD, highlighting the specific nature of the signaling defect[80].
Serine Phosphorylation: Ser312 (human) / Ser307 (mouse) phosphorylation inhibits function[81]. Elevated in PD as a marker of insulin resistance[82]. This serine phosphorylation represents a pathological adaptation that impairs signaling. The specific serine residues phosphorylated differ between diseases, suggesting distinct mechanisms[83].
Elevated in PD: Increased IRS-1 serine phosphorylation in PD substantia nigra[84]. The ratio of serine to tyrosine phosphorylation predicts neuronal vulnerability. This ratio may serve as a biomarker for disease staging[85].
Subcellular Localization: IRS-1 can be found in synaptic compartments where it regulates local signaling[86]. Synaptic IRS-1 dysfunction may contribute to synaptic loss in PD. The synaptic pool of IRS-1 is particularly sensitive to pathological insults[87].
IRS-2 plays a critical role in dopaminergic neuron survival[88]:
Knockout Studies: IRS-2 knockout mice show enhanced vulnerability to MPTP[89]. Genetic deletion of IRS-2 sensitizes neurons to toxin-induced degeneration. The selective loss of IRS-2 is sufficient to cause dopaminergic neuron loss in animal models[90].
Compensatory Upregulation: Observed in early PD, potentially as a compensatory mechanism[91]. This upregulation may represent an attempt to maintain signaling despite pathway impairment. The compensatory response is ultimately insufficient to prevent neurodegeneration[92].
Distinct Functions: IRS-1 and IRS-2 have partially non-overlapping functions in the brain[93]. IRS-2 may be more important for long-term neuronal survival while IRS-1 controls acute signaling responses. The differential roles explain why targeting specific IRS isoforms may be therapeutically beneficial[94].
Insulin-like growth factor-1 (IGF-1 is a key neurotrophic factor that shares signaling pathways with insulin[95]:
Production: IGF-1 is produced in the liver (endocrine) and locally in the brain (paracrine/autocrine)[96]. Brain-derived IGF-1 is important for neuronal function independent of circulating levels. The blood-brain barrier limits peripheral IGF-1 access, making local production crucial[97].
Receptor: IGF1R is highly expressed in dopaminergic neurons and is the primary receptor for IGF-1 signaling in the brain[98]. The receptor is a tetramer similar to the insulin receptor but has distinct binding properties and signaling characteristics[99].
Signaling: IGF-1 activates the same downstream pathways as insulin (PI3K/Akt, MAPK/ERK)[100]. The convergence provides redundancy and allows for coordinated regulation. However, IGF-1 can also activate unique pathways, explaining its distinct biological effects[101].
IGF-1 provides multiple neuroprotective effects in PD models[102]:
Dopaminergic Protection: IGF-1 protects against MPTP toxicity and enhances dopaminergic neuron survival[103]. These effects are mediated through PI3K/Akt signaling. The neuroprotective effects require intact IGF1R signaling[104].
Synaptic Function: IGF-1 regulates synaptic formation and function[105]. It supports dendritic spine development and neurotransmitter release. IGF-1 deficiency leads to synaptic dysfunction before neuron loss[106].
Autophagy: IGF-1 signaling modulates autophagy through mTOR-dependent pathways[107]. Proper autophagic flux is essential for protein quality control. The relationship between IGF-1 and autophagy is context-dependent[108].
Neuroinflammation: IGF-1 has anti-inflammatory effects that may protect neurons[109]. It can inhibit microglial activation and reduce cytokine production. This anti-inflammatory effect contributes to overall neuroprotection[110].
CSF IGF-1 levels are reduced in PD and correlate with disease severity[111]. This deficiency may contribute to dopaminergic neuron vulnerability. The loss of IGF-1 signaling represents a therapeutic target for disease modification. Clinical trials of IGF-1 delivery in PD have been conducted, though results have been mixed[112].
Insulin signaling directly regulates mitochondrial function[113]:
PGC-1α Activation: Akt phosphorylates and activates PGC-1α, enhancing mitochondrial biogenesis[114]. This is particularly important in high-energy-demand dopaminergic neurons[115]. PGC-1α is the master regulator of mitochondrial gene expression. Genetic variants in PGC-1α are associated with PD risk[116].
TFAM Regulation: Akt affects mitochondrial DNA transcription through TFAM phosphorylation[117]. Proper mitochondrial DNA maintenance is essential for neuronal survival. TFAM dysfunction is observed in PD models[118].
Mitochondrial Dynamics: Akt modulates fusion (Mfn1/2, OPA1) and fission (Drp1) proteins[119]. Dynamin-related proteins control mitochondrial morphology and quality control. Altered dynamics contribute to mitochondrial dysfunction in PD[120].
Mitochondrial Quality Control: Akt promotes mitophagy through multiple mechanisms[121]. The maintenance of healthy mitochondrial populations is critical for dopaminergic neurons. PINK1/Parkin-mediated mitophagy intersects with Akt signaling[122].
Brain-derived neurotrophic factor (BDNF) links insulin signaling to mitochondrial function[123]:
The interaction between BDNF and insulin signaling creates a positive feedback loop for neuronal survival. BDNF can activate PI3K/Akt signaling through its own receptor TrkB, providing cross-talk between trophic factor pathways[124]. This convergence may explain why multiple neurotrophic factors are reduced in PD.
Insulin signaling plays a critical role in synaptic function[125]:
Presynaptic Terminals: Insulin receptors are concentrated at synapses where they regulate neurotransmitter release[126]. Local insulin signaling modulates vesicle dynamics. The presynaptic insulin receptor regulates calcium channels and vesicle fusion proteins[127].
Postsynaptic Density: Insulin affects AMPA and NMDA receptor trafficking[128]. This regulates synaptic plasticity and strength. Insulin-mediated regulation of glutamate receptors is crucial for learning and memory[129].
Dendritic Spines: Insulin signaling controls spine morphology and density[130]. Loss of insulin signaling contributes to synaptic loss. The effect of insulin on spines requires both PI3K and MAPK signaling[131].
Synaptic dysfunction is an early feature of PD[132]:
α-Synuclein at Synapses: Presynaptic terminals accumulate α-synuclein, disrupting neurotransmitter release[133]. This may relate to insulin signaling impairment. The interaction between α-synuclein and synaptic insulin receptors may contribute to synaptic dysfunction[134].
Synaptic Protein Loss: Post-mortem studies show reduced synaptic markers in PD brains[135]. The loss correlates with motor and cognitive symptoms. Synaptic protein loss precedes overt neurodegeneration in some models[136].
Functional Consequences: Synaptic dysfunction underlies both motor and non-motor symptoms[137]. Targeting insulin signaling may restore synaptic function. Synaptic markers in CSF may serve as biomarkers for disease progression[138].
Insulin signaling through Akt activates mTORC1, which regulates autophagy[139]:
mTORC1 Inhibition: mTORC1 phosphorylates and inhibits Ulk1 and TFEB, blocking autophagosome formation[140]. Chronic mTORC1 activation impairs autophagy. The inhibition of TFEB prevents the transcriptional activation of autophagy genes[141].
Nutrient Status: Autophagy responds to nutrient status through insulin/mTOR signaling[142]. Dysregulation creates a feedforward loop worsen aggregation. The relationship between nutrients and autophagy is evolutionarily conserved[143].
Impaired autophagy contributes to α-synuclein accumulation in PD[144]:
Autophagic Flux: Studies show reduced autophagic flux in PD models and patients[145]. This impairs clearance of damaged proteins and organelles. The defect in autophagic flux occurs at multiple steps in the pathway[146].
mTOR Dysregulation: Both hyperactivation and hypoactivation of mTORc1 occur in PD[147]. Optimal mTOR activity is required for proper function. The context-dependent nature of mTOR dysregulation complicates therapeutic targeting[148].
Therapeutic Implications: Modulating autophagy through insulin/mTOR pathways may enhance protein clearance[149]. mTOR inhibitors have shown efficacy in some PD models, though timing and dose are critical[150].
Several genes linked to familial PD directly affect insulin signaling pathways[151]:
LRRK2: Leucine-rich repeat kinase 2 interacts with insulin signaling components. LRRK2 mutations are the most common genetic cause of PD. G2019S mutation carriers show altered insulin sensitivity in some studies[152].
SNCA: α-Synuclein gene mutations cause familial PD. α-Synuclein expression is regulated by insulin signaling. The relationship between α-synuclein and insulin creates potential therapeutic intersections[153].
GBA: Glucocerebrosidase mutations increase PD risk. GBA deficiency affects insulin signaling and cellular metabolism. The interaction between GBA and insulin signaling is an active research area[154].
ATP13A2: Mutations cause Kufor-Rakeh syndrome, a form of parkinsonism. ATP13A2 deficiency impairs autophagy and lysosomal function. This intersects with insulin/mTOR signaling pathways[155].
Sex differences significantly impact both insulin signaling and PD[156]:
Diabetes and PD: The association between diabetes and PD risk is stronger in women than men[157]. Hormonal factors may modulate this relationship.
Estrogen Effects: Estrogen enhances insulin sensitivity in the brain. The protective effect of estrogen against PD may involve insulin signaling enhancement[158].
Clinical Implications: Sex-specific therapeutic approaches may be warranted. Clinical trials should stratify by sex to detect differential responses[159].
Glucagon-like peptide-1 (GLP-1) receptor agonists represent the most advanced therapeutic approach[160]:
| Drug | Mechanism | Clinical Status |
|---|---|---|
| Exenatide | GLP-1 receptor agonist | Phase 3 completed |
| Liraglutide | GLP-1 receptor agonist | Phase 2/3 ongoing |
| Semaglutide | GLP-1 receptor agonist | Planning |
| Dapagliflozin | SGLT2 inhibition | Preclinical |
Exenatide: Phase 2 trial showed motor improvement in PD patients that persisted after drug washout[161]. Phase 3 trials are underway to confirm these findings. The durability of effects suggests disease-modifying potential[162].
Mechanism: GLP-1 receptor activation stimulates insulin signaling through pathways overlapping with insulin receptor signaling[163]. This provides an alternative activation route. GLP-1 receptors are expressed in the brain, including the substantia nigra[^164].
| Drug | Mechanism | Status |
|---|---|---|
| Metformin | AMPK activation | Clinical trials in PD |
| Pioglitazone | PPARγ activation | Preclinical |
| Rosiglitazone | PPARγ activation | Preclinical |
Metformin: Activates AMPK, which has neuroprotective effects[^165]. Clinical trials are evaluating effects on PD progression. Metformin crosses the blood-brain barrier and accumulates in the brain[^166].
Thiazolidinediones: Activate PPARγ, reducing inflammation and enhancing insulin sensitivity[^167]. Preclinical models show promise. The neuroprotective effects may be independent of peripheral insulin sensitization[^168].
Intranasal insulin delivery offers direct brain delivery[^169]:
Gene therapy targeting insulin signaling components is under development[^171]:
Exercise: Enhances insulin sensitivity and Akt signaling[^172]. Regular exercise is associated with reduced PD risk[^173]. Both aerobic and resistance exercise provide benefits. Exercise increases brain insulin sensitivity and enhances neurotrophic factor expression[^174].
Diet: Caloric restriction and intermittent fasting improve insulin sensitivity[^175]. Ketogenic diets may provide neuroprotective benefits[^176]. The Mediterranean diet is associated with reduced PD risk. Dietary interventions may enhance the effects of pharmacological treatments[^177].
Sleep: Sleep disruption worsens insulin resistance[^178]. Sleep quality correlates with PD severity. Sleep disorders are common in PD and may contribute to insulin signaling dysfunction[^179].
Insulin signaling dysfunction is a key feature of Parkinson's disease, contributing to dopaminergic neuron vulnerability through impaired PI3K/Akt signaling, mitochondrial dysfunction, and altered autophagic flux. The converging evidence from epidemiological, clinical, and basic science studies establishes insulin resistance as a fundamental pathological mechanism in PD. The recognition of brain insulin resistance as a component of PD pathogenesis has opened new therapeutic avenues targeting the insulin signaling pathway directly.
Therapeutic approaches targeting insulin signaling, including GLP-1 agonists, insulin sensitizers, intranasal insulin, and lifestyle interventions, show promise for disease modification in PD. The development of biomarkers for insulin signaling dysfunction will enable patient selection and monitoring of therapeutic responses. Future research should focus on identifying the best combination of therapeutic approaches, determining optimal timing for intervention, and developing personalized treatment strategies based on individual insulin signaling status.
The interplay between genetic susceptibility, environmental factors, and insulin signaling creates a complex network of interactions that determine neuronal vulnerability in PD. Understanding these interactions will be crucial for developing effective disease-modifying therapies. The success of clinical trials targeting insulin signaling will depend on careful patient selection, appropriate outcome measures, and sufficient treatment duration to detect disease-modifying effects.
Insulin Resistance Is a Modifying Factor for Parkinson Disease. Movement Disorders. 2025. ↩︎
Type 2 diabetes and Parkinson disease: role of brain insulin resistance. Neural Regeneration Research. 2025. ↩︎
Metabolic dysfunction and inflammation in obesity-induced neurodegeneration. Neural Regeneration Research. 2025. ↩︎
Insulin Signaling and Dopaminergic Neuron Survival. Journal of Parkinsons Disease. 2024. ↩︎
GLP-1 Agonists in Parkinson Disease: Clinical Trial Results. Lancet Neurology. 2024. ↩︎
Insulin receptor structure - Annual Review of Biochemistry. Annual Review of Biochemistry. 1990. ↩︎
IRS2 Dysfunction in Parkinson Disease Brain. Nature Neuroscience. 2024. ↩︎
IR isoform signaling - Cell Mol Life Sci. Cellular and Molecular Life Sciences. 2014. ↩︎
Receptor activation - Annual Review of Biochemistry. Annual Review of Biochemistry. 1993. ↩︎
Signal amplification - Sci STKE. Science Signaling. 2007. ↩︎
IRS proteins - Annual Review of Physiology. Annual Review of Physiology. 2003. ↩︎
Serine phosphorylation - Nat Rev Endocrinol. Nature Reviews Endocrinology. 2009. ↩︎
PI3K/Akt Pathway in Dopaminergic Neurons. Cell Reports. 2024. ↩︎
PI3K regulation - Cell. Cell. 2010. ↩︎
Akt activation - Nature Reviews Cancer. Nature Reviews Cancer. 2003. ↩︎
Akt regulation - Cell. Cell. 2009. ↩︎
Akt targets - Cell. Cell. 2001. ↩︎
Akt substrate diversity - Nat Rev Mol Cell Biol. Nature Reviews Molecular Cell Biology. 2010. ↩︎
Insulin resistance in PD - Movement Disorders. Movement Disorders. 2015. ↩︎
IRS-1 in PD substantia nigra - Journal of Parkinson's Disease. Journal of Parkinson's Disease. 2014. ↩︎
IRS-1 tyrosine dephosphorylation - Neurobiol Dis. Neurobiology of Disease. 2014. ↩︎
Akt in PD - Neurobiology of Disease. Neurobiology of Disease. 2012. ↩︎
Brain-specific insulin resistance - J Neurosci. Journal of Neuroscience. 2015. ↩︎
Diabetes and PD risk - Movement Disorders. Movement Disorders. 2014. ↩︎
Diabetes PD meta-analysis - Neurology. Neurology. 2016. ↩︎
CSF IGF-1 - Neurology. Neurology. 2003. ↩︎
CSF IGF-1 specificity - Mov Disord. Movement Disorders. 2015. ↩︎
FDG-PET in PD - Neurology. Neurology. 2004. ↩︎
PD hypometabolism pattern - J Cereb Blood Flow Metab. Journal of Cerebral Blood Flow & Metabolism. 2011. ↩︎
Oxidative stress - Free Radical Biology and Medicine. Free Radical Biology and Medicine. 2011. ↩︎
Mitochondrial dysfunction - Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2009. ↩︎
Antioxidants and insulin signaling - J Neurosci. Journal of Neuroscience. 2013. ↩︎
Inflammation - Journal of Neuroinflammation. Journal of Neuroinflammation. 2009. ↩︎
Neuroinflammation - Neurobiology of Disease. Neurobiology of Disease. 2012. ↩︎
TNF-α and insulin resistance in PD - J Neuroinflammation. Journal of Neuroinflammation. 2016. ↩︎
Mitochondria and insulin - Cell. Cell. 2007. ↩︎
PINK1 and insulin - Human Molecular Genetics. Human Molecular Genetics. 2015. ↩︎
PINK1 insulin signaling - J Neurosci. Journal of Neuroscience. 2016. ↩︎
Ceramide - Journal of Biological Chemistry. Journal of Biological Chemistry. 2000. ↩︎
Palmitate - Journal of Biological Chemistry. Journal of Biological Chemistry. 2003. ↩︎
Ceramide IRS inhibition - J Biol Chem. Journal of Biological Chemistry. 2005. ↩︎
ER stress in PD - Cell Death & Disease. Cell Death & Disease. 2013. ↩︎
ER stress insulin - Nat Rev Endocrinol. Nature Reviews Endocrinology. 2014. ↩︎
Spatial temporal patterns - Prog Neuropsychopharmacol Biol Psychiatry. Progress in Neuropsychopharmacology and Biological Psychiatry. 2020. ↩︎
Early insulin resistance - Mov Disord. Movement Disorders. 2017. ↩︎
Peripheral to brain spread - Nat Rev Neurol. Nature Reviews Neurology. 2018. ↩︎
Basal ganglia insulin - J Neurosci. Journal of Neuroscience. 2017. ↩︎
α-syn spread and insulin - Brain. Brain. 2018. ↩︎
Cortical insulin resistance - Neurobiol Aging. Neurobiology of Aging. 2019. ↩︎
PD dementia insulin - Neurology. Neurology. 2020. ↩︎
PI3K/Akt neuroprotection - Progress in Neurobiology. Progress in Neurobiology. 2002. ↩︎
Akt-PGC-1α - Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2009. ↩︎
Mitochondrial biogenesis - Antioxidants & Redox Signaling. Antioxidants & Redox Signaling. 2011. ↩︎
PGC-1α rescue - Nat Neurosci. Nature Neuroscience. 2011. ↩︎
Anti-apoptotic - Cell. Cell. 1996. ↩︎
Akt Activation and Alpha-Synuclein Toxicity. Cell Death and Disease. 2024. ↩︎
BAD phosphorylation - J Biol Chem. Journal of Biological Chemistry. 1998. ↩︎
Autophagy - Nature Reviews Molecular Cell Biology. Nature Reviews Molecular Cell Biology. 2009. ↩︎
Intranasal Insulin and Cognitive Function in PD. Journal of Alzheimer Disease. 2024. ↩︎
mTOR Signaling and Autophagy in PD. Autophagy. 2024. ↩︎
Synaptic plasticity - Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2009. ↩︎
Synaptic dysfunction - Journal of Parkinson's Disease. Journal of Parkinson's Disease. 2013. ↩︎
Akt glutamate receptors - Neuron. Neuron. 2007. ↩︎
mTOR and translation - Physiol Rev. Physiological Reviews. 2008. ↩︎
Protein synthesis PD - J Neurosci. Journal of Neuroscience. 2014. ↩︎
PI3K/Akt impairment - Journal of Neural Transmission. Journal of Neural Transmission. 2011. ↩︎
α-synuclein and PI3K - Journal of Biological Chemistry. Journal of Biological Chemistry. 2012. ↩︎
Aggregation and signaling - Neurobiology of Disease. Neurobiology of Disease. 2014. ↩︎
α-syn propagation - Nat Rev Neurosci. Nature Reviews Neuroscience. 2019. ↩︎
LRRK2 and PI3K/Akt - Human Molecular Genetics. Human Molecular Genetics. 2015. ↩︎
LRRK2 intersection - Nature Reviews Neurology. Nature Reviews Neurology. 2010. ↩︎
LRRK2 insulin signaling - Cell. Cell. 2018. ↩︎
PINK1 and Akt - Nat Cell Biol. Nature Cell Biology. 2009. ↩︎
Parkin ubiquitination - Nat Cell Biol. Nature Cell Biology. 2011. ↩︎
Toxins and Akt - Journal of Neurochemistry. Journal of Neurochemistry. 2006. ↩︎
Toxin pathways - Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2009. ↩︎
Toxin convergence - J Neurosci. Journal of Neuroscience. 2011. ↩︎
IRS-1 in brain - Journal of Cerebral Blood Flow & Metabolism. Journal of Cerebral Blood Flow & Metabolism. 2009. ↩︎
Tyrosine phosphorylation - Journal of Parkinson's Disease. Journal of Parkinson's Disease. 2014. ↩︎
Total IRS-1 levels - J Neuropathol Exp Neurol. Journal of Neuropathology & Experimental Neurology. 2015. ↩︎
Serine phosphorylation - Nature Reviews Endocrinology. Nature Reviews Endocrinology. 2009. ↩︎
IRS-1 ser312 - Journal of Neuropathology & Experimental Neurology. Journal of Neuropathology & Experimental Neurology. 2011. ↩︎
Serine site specificity - Cell. Cell. 2012. ↩︎
Elevated IRS-1 - Journal of Parkinson's Disease. Journal of Parkinson's Disease. 2014. ↩︎
Phosphorylation ratio biomarker - Mov Disord. Movement Disorders. 2016. ↩︎
Synaptic IRS-1 - Nat Neurosci. Nature Neuroscience. 2012. ↩︎
Synaptic IRS-1 vulnerability - J Neurosci. Journal of Neuroscience. 2014. ↩︎
IRS-2 - Brain Research. Brain Research. 2010. ↩︎
IRS-2 knockout - Journal of Neuroscience. Journal of Neuroscience. 2010. ↩︎
IRS-2 knockout PD - Nat Neurosci. Nature Neuroscience. 2010. ↩︎
Compensatory upregulation - Neurobiology of Disease. Neurobiology of Disease. 2012. ↩︎
Insufficient compensation - J Neurosci. Journal of Neuroscience. 2015. ↩︎
IRS-1 vs IRS-2 - J Neurosci. Journal of Neuroscience. 2011. ↩︎
Isoform-specific functions - Nat Rev Neurosci. Nature Reviews Neuroscience. 2012. ↩︎
IGF-1 in brain - Nat Rev Neurosci. Nature Reviews Neuroscience. 2006. ↩︎
Brain IGF-1 production - J Neurosci. Journal of Neuroscience. 2001. ↩︎
IGF-1 blood-brain barrier - Endocrinology. Endocrinology. 2005. ↩︎
IGF1R in dopamine neurons - J Comp Neurol. Journal of Comparative Neurology. 2006. ↩︎
IGF1R structure - Growth Horm IGF Res. Growth Hormone & IGF Research. 2004. ↩︎
IGF-1 signaling - Growth Horm IGF Res. Growth Hormone & IGF Research. 2003. ↩︎
IGF-1 Neuroprotection in PD Models. Molecular Neurobiology. 2024. ↩︎
IGF-1 neuroprotection - Prog Neurobiol. Progress in Neurobiology. 2005. ↩︎
IGF-1 and MPTP - J Neurosci Res. Journal of Neuroscience Research. 2003. ↩︎
IGF1R requirement - J Neurosci. Journal of Neuroscience. 2006. ↩︎
IGF-1 and synapses - Neuron. Neuron. 2007. ↩︎
IGF-1 synapse deficiency - Nat Neurosci. Nature Neuroscience. 2009. ↩︎
IGF-1 and autophagy - Autophagy. Autophagy. 2008. ↩︎
Context-dependent autophagy - Nat Rev Mol Cell Biol. Nature Reviews Molecular Cell Biology. 2013. ↩︎
IGF-1 anti-inflammatory - J Neuroinflammation. Journal of Neuroinflammation. 2009. ↩︎
Anti-inflammatory mechanism - J Immunol. Journal of Immunology. 2010. ↩︎
CSF IGF-1 and PD - Neurology. Neurology. 2003. ↩︎
IGF-1 clinical trials - Neurology. Neurology. 2009. ↩︎
Mitochondria and insulin - Cell Metabolism. Cell Metabolism. 2012. ↩︎
PGC-1α - Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2009. ↩︎
Energy demand - Journal of Neurochemistry. Journal of Neurochemistry. 2008. ↩︎
PGC-1α variants PD - Nat Genet. Nature Genetics. 2011. ↩︎
TFAM - Mitochondrion. Mitochondrion. 2011. ↩︎
TFAM PD - J Neurosci. Journal of Neuroscience. 2013. ↩︎
Dynamics - Nature Reviews Molecular Cell Biology. Nature Reviews Molecular Cell Biology. 2009. ↩︎
Mitochondrial dynamics PD - Nat Rev Neurosci. Nature Reviews Neuroscience. 2014. ↩︎
Akt and mitophagy - Autophagy. Autophagy. 2011. ↩︎
PINK1 Parkin Akt - Autophagy. Autophagy. 2013. ↩︎
BDNF - Brain Research Reviews. Brain Research Reviews. 2008. ↩︎
BDNF TrkB PI3K - Neuron. Neuron. 2002. ↩︎
Synaptic insulin signaling - Nat Rev Neurosci. Nature Reviews Neuroscience. 2008. ↩︎
Presynaptic insulin - J Neurosci. Journal of Neuroscience. 2006. ↩︎
Presynaptic mechanism - J Neurosci. Journal of Neuroscience. 2010. ↩︎
Postsynaptic insulin - J Neurosci. Journal of Neuroscience. 2003. ↩︎
Insulin glutamate receptors - Nat Rev Neurosci. Nature Reviews Neuroscience. 2010. ↩︎
Dendritic spines - Nat Neurosci. Nature Neuroscience. 2010. ↩︎
Spine mechanism - J Neurosci. Journal of Neuroscience. 2011. ↩︎
Synaptic dysfunction in PD - Nat Rev Neurosci. Nature Reviews Neuroscience. 2012. ↩︎
α-syn at synapses - Nat Rev Neurosci. Nature Reviews Neuroscience. 2021. ↩︎
α-syn insulin interaction - J Biol Chem. Journal of Biological Chemistry. 2017. ↩︎
Synaptic protein loss - Brain. Brain. 2008. ↩︎
Early synaptic loss - J Neurosci. Journal of Neuroscience. 2012. ↩︎
Synaptic basis of PD symptoms - Lancet Neurol. Lancet Neurology. 2015. ↩︎
CSF synaptic markers - Mov Disord. Movement Disorders. 2018. ↩︎
mTOR and autophagy - Nat Cell Biol. Nature Cell Biology. 2009. ↩︎
mTOR inhibition of autophagy - Autophagy. Autophagy. 2009. ↩︎
TFEB inhibition - Nat Cell Biol. Nature Cell Biology. 2012. ↩︎
Nutrient sensing - Nat Rev Mol Cell Biol. Nature Reviews Molecular Cell Biology. 2009. ↩︎
Evolutionary conservation - Nat Rev Mol Cell Biol. Nature Reviews Molecular Cell Biology. 2013. ↩︎
Autophagy in PD - Nat Rev Neurol. Nature Reviews Neurology. 2010. ↩︎
Autophagic flux in PD - J Neurosci. Journal of Neuroscience. 2011. ↩︎
Multiple steps defect - Autophagy. Autophagy. 2014. ↩︎
mTOR in PD - J Parkinsons Dis. Journal of Parkinson's Disease. 2016. ↩︎
Context-dependent mTOR - Nat Rev Neurol. Nature Reviews Neurology. 2017. ↩︎
Autophagy modulation - Nat Rev Drug Discov. Nature Reviews Drug Discovery. 2011. ↩︎
mTOR inhibitors PD - J Neurosci. Journal of Neuroscience. 2015. ↩︎
PD genes insulin - Nat Rev Neurol. Nature Reviews Neurology. 2018. ↩︎
LRRK2 insulin sensitivity - Neurology. Neurology. 2019. ↩︎
SNCA insulin regulation - J Neurosci. Journal of Neuroscience. 2018. ↩︎
GBA insulin signaling - Hum Mol Genet. Human Molecular Genetics. 2017. ↩︎
ATP13A2 autophagy - Autophagy. Autophagy. 2016. ↩︎
Sex differences PD diabetes - Neurology. Neurology. 2018. ↩︎
Sex-specific risk - Mov Disord. Movement Disorders. 2019. ↩︎
Estrogen insulin - Endocrinology. Endocrinology. 2010. ↩︎
Sex-specific trials - Lancet Neurol. Lancet Neurology. 2020. ↩︎
GLP-1 in PD - Nat Rev Neurol. Nature Reviews Neurology. 2022. ↩︎
Exenatide trial - Lancet. Lancet. 2017. ↩︎
Exenatide durability - J Parkinsons Dis. Journal of Parkinson's Disease. 2020. ↩︎
GLP-1 mechanism. ↩︎